|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).
07/19/18AVEO Oncology Issues Statement Regarding Revised TIVO-3 Trial GuidanceRead More
06/25/18AVEO Oncology Added to the Russell 2000, Russell 3000, and Russell Microcap IndexesRead More
05/31/18AVEO Oncology to Present at the Jefferies 2018 Healthcare ConferenceRead More
Corporate PresentationAVEO Oncology Corporate Presentation